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Emergency coronary angioplasty. Several large clinical 
trials (l-3) have determined that thrombolytic therapy estab- 
lishes early coronary reperfusion and improves survival of 
patients with acute myocardial infarction. In the Second 
Thrombolysis in Myocardial Infarction trial (TIM1 II-A) (4) 
a randomized clinical trial comparing emergency with de- 
layed coronary angioplasty, 75% of infarct-related vessels 
were found to be patent an average of 1.4 h after treatment 
with recombinant tissue plasminogen activator (rt-PA) and in 
the group with delayed treatment, 83% of such vessels were 
patent after an average of 32.7 h. A major problem with 
thrombolytic therapy is the frequent finding of a significant 
residual obstruction after reperfusion and the concomitant 
10% to 20% risk of significant reocclusion that in some 
patients results in reinfarction or death. In an attempt to 
alleviate this risk, some physicians have pursued an aggres- 
sive strategy of emergency coronary angioplasty as a routine 
treatment modality for patients with acute myocardial infarc- 
tion. 
In this issue of the Journal, Ellis et al. (5) report their 
experience with 500 consecutive patients treated with coro- 
nary angioplasty within 24 h of an acute myocardial infarc- 
tion; 49% of this group also received an intravenous throm- 
bolytic drug. At the time of cardiac catheterization, 60% of 
patients had an occluded infarct-related vessel; 30% were 
treated ~6 h after symptom onset. The investigators found 
that successful angioplasty was independently correlated 
with improved in-hospital survival of patients with cardio- 
genie shock and those with an anterior myocardial infarc- 
tion; a beneficial trend toward improved survival was noted 
in patients with an inferior wall infarction and precordial ST 
segment depression and in hypotensive patients. The inves- 
tigators (5) conclude that their data allow patient stratifica- 
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tion in the emergency room to groups likely or unlikely to 
derive benefit from immediate cardiac catheterization and 
coronary angioplasty. However, their patients who had an 
unsuccessful angioplasty procedure had a relatively high 
mortality rate (36% and 14.7% for patients with an anterior 
and an inferior myocardial infarction, respectively), and it is 
not surprising that after adjustment for covariates, a success- 
ful procedure was more often associated with decreased 
in-hospital mortality than was an unsuccessful procedure. 
The data confirm an earlier report by Rothbaum et al. (6) 
who noted a 37% hospital mortality rate among patients with 
acute infarction who had an unsuccessful emergency coro- 
nary angioplasty procedure. 
To truly test the hypothesis that the authors (5) advocate, 
a control group that does not undergo cardiac catheterization 
and coronary angioplasty are required. The results of three 
randomized trials (4,7,8) comparing emergency with delayed 
or no coronary angioplasty for patients with acute infarction 
are not encouraging for the routine emergency angioplasty 
strategy even though patients were entered early after symp- 
tom onset when the potential for myocardial salvage was 
greatest (Table 1). In hospital mortality, hemorrhagic com- 
plications and the need for emergency coronary bypass 
grafting were greater in patients randomized to the emer- 
gency strategy; reinfarction and reocclusion rates were 
similar. Thus, routine emergency coronary angioplasty for 
acute myocardial infarction appears to increase hospital 
mortality and, when the procedure fails, may be harmful. 
Subgroup analysis: emergency versus delayed angioplasty. 
The in-hospital mortality rate in the series of Ellis et al. (5) 
was 8.6% and 4.1% for patients with anterior and inferior 
myocardial infarction, respectively, after patients >70 
years, those with cardiogenic shock and those treated 26 h 
after symptom onset were excluded. Thus, in some respects, 
the patients were similar to those in Table 1, with a mortality 
rate higher in the series of Ellis et al. than in patients 
randomized to the delayed coronary angioplasty strategy. In 
TIM1 II-A, patients not considered to be at low risk (those 
with prior myocardial infarction, or, at the time of initial 
evaluation: anterior myocardial infarction, pulmonary rales 
over >1/3 of lung fields, hypotension, sinus tachycardia, 
atria1 fibrillation, age >70 years) had a similar mortality rate 
when they were randomized to emergency as compared with 
delayed angioplasty (8.4% versus 7.5%) (4). Thus, even after 
subgroup analysis, emergency coronary angioplasty as a 
routine strategy does not appear to be any more effective 
than delayed angioplasty. 
Is routine coronary angioplasty necessary at all? The 
TIM1 II-B trial recently reported results of 3,262 patients 
treated with rt-PA who were randomly allocated to a strat- 
egy of cardiac catheterization and angioplasty of the infarct- 
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Table 1. Results From Three Randomized Trials of Emergent 
Versus Delayed or No Coronary Angioplasty for Acute 
Myocardial Infarction 
TAMI (7) ECSG (8) TIMI-IIA (4) 
E D E M E D 
No. of patients 99 98 183 184 195 194 
In-hospital mortality 4 I I 3 7.2 5.1 
Reinfarction NR NR 4 7 6.1 4.1 
Reocclusion rate II I3 14 17 - I7 IS 
Discharge LVEF 53.2 56.4 51.0 51.0 50.3 49.0 
D = delayed; E = emergency: ECSG = European Cooperative Study 
Group for tissue plasminogen activator: LVEF = left ventricular ejection 
fraction; M = medical management: MI = myocardial infarction: NR = not 
reported; TAM1 = Thrombolysis and Angioplasty in Myocardial InfarctIon 
trial: TIM1 = Thrombolysis in Myocardial Infarction trial. 
related artery 18 to 48 h after thrombolysis compared with a 
conservative strategy in which cardiac catheterization and 
revascularization were employed only for spontaneous or 
exercise-induced myocardial ischemia (9). Recurrent myo- 
cardial ischemic events within 2 weeks of the index infarc- 
tion occurred in 21% and 26%, respectively, of patients 
randomized to the invasive versus conservative strategy. At 
6 weeks, the mortality rate was 5.2% versus 4.7% in the 
invasive versus conservative treatment groups, and nonfatal 
myocardial infarction rates were 5.9% and 5.4%, respec- 
tively. At 1 year, survival was similar in both treatment 
arms. Left ventricular function by radionuclide analysis was 
similar in both groups. The concomitant use of intravenous 
metoprolol in low risk patients further decreased the risk of 
death or myocardial infarction at 6 weeks when therapy was 
initiated within 2 h of enrollment into the study. Thus, the 
routine use of delayed coronary angioplasty 18 to 48 h after 
rt-PA therapy for acute myocardial infarction is no better 
than a conservative strategy with cardiac catheterization and 
revascularization reserved for well defined clinical indica- 
tions. 
Who should be considered for emergency coronary angio- 
plasty? A minority of patients fail to exhibit coronary reper- 
fusion with thrombolytic therapy, and these patients are 
difficult to identify clinically. Newer enzymatic or radionu- 
elide tests may be helpful in determining early reperfusion. 
but further research in this area is necessary. Patients who 
continue to experience important ischemic cardiac pain or 
important worsening of ST segment elevation in the hour or 
so after the onset of thrombolytic therapy, those who 
achieve initial reperfusion but subsequently develop symp- 
tomatic reocclusion or patients with hemodynamic instabil- 
ity after adequate volume repletion should be considered for 
emergency cardiac catheterization and revascularization 
when possible. Another subgroup in whom this approach 
might be reasonable comprises patients with acute myocar- 
dial infarction who present early after symptom onset but 
have contraindications to thrombolysis. These subgroups, in 
which many patients have an occluded infarct-related vessel, 
are at high risk, with a significant increased procedure and 
in-hospital mortality rate. Of the 51 in-hospital deaths re- 
ported in the series of Ellis et al. (51, 13.7% occurred in the 
laboratory and 45. I% within 24 h of cardiac catheterization 
(5). Stack et al. (10) report an in-hospital mortality rate of 
15% among patients with an occluded infarct-related artery 
who underwent angioplasty as an emergency procedure 
compared with 5% when the infarct vessel was open at the 
time of initial catheterization. 
Conclusions. The University of Michigan Group has 
made major contributions to our understanding of the role of 
thrombolytic therapy and coronary angioplasty in the short- 
and long-term management of clinical patient subsets with 
acute myocardial infarction. There continue to be important 
unresolved issues regarding reperfusion for acute myocar- 
dial infarction (1 I) but, in my opinion, the argument that 
routine coronary angioplasty is an optimal treatment strat- 
egy for patients with acute myocardial infarction is not 
supported by the data. 
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